Cell technology company iXCells Biotechnologies has partnered with Rosebud Biosciences to advance organoid-based models for rare diseases. 

The partnership will set out to develop a personalised, human-based approach for predicting drug safety and informing translational decision-making in rare diseases. 

iXCells will integrate Rosebud’s organoid generation and characterisation expertise into its existing iPSC solutions, enabling access to complex 3D human systems that better represent tissue-level biology and simulate therapeutic response.  

The combined workflow brings together iXCells’ iPSC platform, iPSCore, with Rosebud’s AI-driven organoid platform, designed to generate scalable, reproducible human tissue data for drug discovery and safety assessment.  

“Our focus has always been on anticipating what our partners will need next, and Rosebud brings impressive depth in organoid science that aligns perfectly with that vision,” said Steve Smith, Chief Executive Officer of iXCells Biotechnologies. 

“This collaboration enhances our end-to-end platform and expands our ability to deliver next-generation models that reflect human biology with greater depth and accuracy. In areas such as rare diseases, where predicting human-specific safety and response earlier can significantly impact development timelines and patient outcomes, these integrated systems provide critical insight.  

“This partnership reflects the strategic direction we are taking as iXCells scales its platform to support more complex, translationally focused programmes for our partners.” 

“Our partnership with iXCells allows us to make advanced organoid systems more accessible to researchers who need models that better represent human biology,” added Kitch Wilson, Chief Executive Officer and Co-Founder of Rosebud Biosciences. 

“By combining our complementary strengths, we can support deeper exploration of disease biology and help drive the next generation of therapeutic discovery.”